TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12541430

Group type: EXPERIMENTAL
Intervention: Active alerting tasks (maths calculation, answering questions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Passive alerting tasks (listening to music, listening to stories)
Number of subjects: 40
Study: 9485968

Group type: EXPERIMENTAL
Intervention: 1 ml hyperbaric 0.5% bupivacaine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 2 ml hyperbaric 0.5% bupivacaine
Number of subjects: 54
Study: 8339699

Group type: EXPERIMENTAL
Intervention: Mixed-age child care group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Same-age child care group
Number of subjects: 59
Study: 2422463

Group type: EXPERIMENTAL
Intervention: Nifedipine (3 doses of 20 mg given sublingually at 8‐h intervals)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 28662370

Group type: EXPERIMENTAL
Intervention: Higher calorie exposure (kcal/kg) received from ICU days 1-6
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Calorie exposure (kcal/kg) received after ICU day 7
Number of subjects: 298
Study: 27312405

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24627629

Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 20
Study: 23292820

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) supermarket (VMall) treatment, 10 sessions of 45 minutes each.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional occupational therapy (OT) cognitive retraining without VR, 10 sessions.
Number of subjects: 12
Study: 20303641

Group type: EXPERIMENTAL
Intervention: CIN Excisor
Number of subjects: 420

Group type: COMPARATOR
Intervention: LLETZ
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: CIN Excisor for CIN 1
Number of subjects: 420

Group type: COMPARATOR
Intervention: LLETZ for CIN 1
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: CIN Excisor for CIN 2
Number of subjects: 420

Group type: COMPARATOR
Intervention: LLETZ for CIN 2
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: CIN Excisor for CIN 3
Number of subjects: 420

Group type: COMPARATOR
Intervention: LLETZ for CIN 3
Number of subjects: 420
Study: 19139601

Group type: EXPERIMENTAL
Intervention: Strict treatment to maintain systolic blood pressure below 140 mmHg
Number of subjects: 4418

Group type: COMPARATOR
Intervention: Mild treatment to maintain systolic blood pressure below 160 but at or above 140 mmHg
Number of subjects: 4418
Study: 16765550

Group type: EXPERIMENTAL
Intervention: HPLC method for all‐trans‐retinol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HPLC method for alpha‐tocopherol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HPLC method for coenzyme Q(10)
Number of subjects: 2
Study: 12860343

Group type: EXPERIMENTAL
Intervention: Endometriosis (I or II rAFS stage)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endometriosis (III or IV rAFS stage)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Follicular ovarian cysts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dermoid tumors of ovaries
Number of subjects: 50
Study: 10967067

Group type: EXPERIMENTAL
Intervention: L-NMMA (6 mg/kg over 5 minutes followed by 60 microg/kg per minute over 55 minutes)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg over 5 minutes followed by 30 microg/kg per minute over 55 minutes)
Number of subjects: 12
Study: 8979626

Group type: EXPERIMENTAL
Intervention: Enalapril monotherapy
Number of subjects: 53
Study: 31165895

Group type: EXPERIMENTAL
Intervention: AT-02
Number of subjects: 44

Group type: COMPARATOR
Intervention: S-01 (sham control)
Number of subjects: 44
Study: 30121686

Group type: EXPERIMENTAL
Intervention: Music guided deep breathing exercise
Number of subjects: 87

Group type: COMPARATOR
Intervention: Listening to music (control)
Number of subjects: 87
Study: 25619927

Group type: EXPERIMENTAL
Intervention: SNAP intervention
Number of subjects: 252
Study: 24569127

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (ACD) at 0.5 μg/day (n = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Maxacalcitol (OCT) (n = 13)
Number of subjects: 32
Study: 24324554

Group type: EXPERIMENTAL
Intervention: Solving math problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performing semantic judgment task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline condition (no additional task)
Number of subjects: 0
Study: 20493364

Group type: EXPERIMENTAL
Intervention: 50 degrees C saline irrigation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Room-temperature (25 degrees C) saline irrigation
Number of subjects: 120
Study: 18024209

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 16479824

Group type: EXPERIMENTAL
Intervention: Obese women after menopause
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Obese women before menopause
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (women with normal BMI)
Number of subjects: 45
Study: 11967633

Group type: EXPERIMENTAL
Intervention: 25 microg CCK-8
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CCK-8 in healthy controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CCK-8
Number of subjects: 13
Study: 10416094

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 7575103

Group type: EXPERIMENTAL
Intervention: Haloperidol at low plasma level (2 ng/mL)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Haloperidol at moderate plasma level (10 ng/mL)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Haloperidol with subsequent lowering of plasma levels
Number of subjects: 65
Study: 2075079

Group type: EXPERIMENTAL
Intervention: Intravenous cefuroxime 1,500 mg plus 500 mg metronidazole
Number of subjects: 396
Study: 7353344

Group type: EXPERIMENTAL
Intervention: Calcium heparin (15,000 U)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sodium heparins (3 types)
Number of subjects: 48
Study: 31088530

Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCEs)
Number of subjects: 4057
Study: 27733466

Group type: EXPERIMENTAL
Intervention: Baseline SF-12 mental component score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen (BUN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatinine level
Number of subjects: 0
Study: 26377054

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2776

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2776

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2776

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (women)
Number of subjects: 2776

Group type: EXPERIMENTAL
Intervention: Diabetes development
Number of subjects: 2776
Study: 24084509

Group type: EXPERIMENTAL
Intervention: Almonds consumed with breakfast (43 g/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Almonds consumed as a morning snack (43 g/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Almonds consumed as an afternoon snack (43 g/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no almonds)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: All almond groups
Number of subjects: 137
Study: 21317775

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (nine 2-hour sessions: 5 education sessions and 4 autogenic relaxation sessions)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 216
Study: 19213769

Group type: EXPERIMENTAL
Intervention: NIV + LTOT
Number of subjects: 144

Group type: COMPARATOR
Intervention: LTOT alone
Number of subjects: 144
Study: 17124017

Group type: EXPERIMENTAL
Intervention: Open fetal pulse oximetry
Number of subjects: 5341

Group type: COMPARATOR
Intervention: Masked fetal pulse oximetry
Number of subjects: 5341
Study: 14977771

Group type: EXPERIMENTAL
Intervention: Visual impairment defined as binocular acuity of less than 6/18
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Age related macular degeneration (AMD)
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Cataract
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Glaucoma
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Myopic degeneration
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Diabetic eye disease
Number of subjects: 1742
Study: 11266478

Group type: EXPERIMENTAL
Intervention: Custom‐made orthoses
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Over‐the‐counter arch supports
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Tension night splints
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 255
Study: 8996142

Group type: COMPARATOR
Intervention: Carboplatin AUC of 4 (AUC4) and cyclophosphamide 500 mg/m2
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 8 (AUC8) and cyclophosphamide 500 mg/m2
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC of 8 (AUC8)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Carboplatin AUC of 4 (AUC4)
Number of subjects: 222
Study: 8512006

Group type: EXPERIMENTAL
Intervention: Metoprolol (up to 200 mg/die intravenously)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 25
Study: 3498402

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flunitrazepam-propanidid
Number of subjects: 40
Study: 29522113

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate, administered in 3 rounds over a 3-day course.
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Control villages (no MDA).
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin and piperaquine-phosphate.
Number of subjects: 2268
Study: 28831390

Group type: EXPERIMENTAL
Intervention: AQUACEL Ag Surgical dressing
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 240
Study: 26576633

Group type: EXPERIMENTAL
Intervention: CBT-based intervention group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition group (treatment as usual)
Number of subjects: 50
Study: 22946700

Group type: EXPERIMENTAL
Intervention: Individualised goal-directed therapy targeting stroke volume and oxygen delivery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (blinded central haemodynamic data)
Number of subjects: 40
Study: 22403976

Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) mouthwash with 6% alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.075% cetylpyridinium chloride (CPC) alcohol-free mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control mouthwash without CPC
Number of subjects: 0
Study: 18512165

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) patches
Number of subjects: 783

Group type: COMPARATOR
Intervention: Control group (stopping or continuing antihypertensive treatments)
Number of subjects: 783
Study: 15778907

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (lidocaine 5% patch, IBSA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12419092

Group type: EXPERIMENTAL
Intervention: 0.05% CsA
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 0.1% CsA
Number of subjects: 128

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 0.1% CsA (post crossover)
Number of subjects: 128
Study: 10614796

Group type: EXPERIMENTAL
Intervention: Initial revascularization strategy
Number of subjects: 558

Group type: COMPARATOR
Intervention: Initial medical care strategy
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Early revascularization
Number of subjects: 558
Study: 7577287

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms kg‐1) with famotidine 20 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (famotidine 20 mg alone)
Number of subjects: 77
Study: 1774006

Group type: EXPERIMENTAL
Intervention: Therapeutic local anesthesia (TLA) with lidocaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 76
Study: 6173480

Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide (Buscopan)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 55
Study: 30967099

Group type: EXPERIMENTAL
Intervention: 1.4 mg/kg oral racemic MDA
Number of subjects: 0
Study: 30295429

Group type: EXPERIMENTAL
Intervention: Rituximab biosimilar GP2013
Number of subjects: 107

Group type: COMPARATOR
Intervention: Reference RTX
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study: 28174038

Group type: EXPERIMENTAL
Intervention: Short retention interval with forward prompts
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Short retention interval with meal-name prompts
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Short retention interval with open prompts
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Short retention interval with reverse prompts
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Long retention interval with forward prompts
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Long retention interval with meal-name prompts
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Long retention interval with open prompts
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Long retention interval with reverse prompts
Number of subjects: 455
Study: 25997508

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate cream (MAL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5-ALA gel (BF-200 ALA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MAL-PDT for basal cell carcinomas (BCCs)
Number of subjects: 30
Study: 23408040

Group type: EXPERIMENTAL
Intervention: Pemetrexed and carboplatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine
Number of subjects: 40
Study: 21741891

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging (USI) during lifting and reaching tasks
Number of subjects: 20
Study: 19567246

Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(7) cfu/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(9) cfu/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SCAR at 10(5) cfu/ml
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Francisella tularensis Live Vaccine Strain (LVS) via SQ at 10(5) cfu/ml
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16397129

Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplantation (ASCT) prepared by melphalan 220 mg/m(2) and 160 mg dexamethasone with or without anti-IL-6 monoclonal antibody (IFM99-04 protocol)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Autologous stem cell transplantation followed by dose-reduced allogeneic stem cell transplantation (IFM99-03 trial)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplantation (ASCT)
Number of subjects: 284
Study: 15132026

Group type: EXPERIMENTAL
Intervention: Normal walking
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Walking whilst swinging arms at twice the natural frequency
Number of subjects: 8
Study: 11709334

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ofloxacin 400 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 16
Study: 9160765

Group type: EXPERIMENTAL
Intervention: Isradipine SRO (IS) 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spirapril (SP) 6 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isradipine plus Spirapril (IS + SP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8425514

Group type: EXPERIMENTAL
Intervention: Glucose (Glc) ingestion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (P) ingestion
Number of subjects: 7
Study: 2965232

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANP against a nonpressor background infusion of ANG II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANP against a background infusion of ANG II
Number of subjects: 0
Study: 31526671

Group type: EXPERIMENTAL
Intervention: BMV < 4
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: BMV 4-13
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: BMV > 13
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: Melanoma histology
Number of subjects: 2092

Group type: EXPERIMENTAL
Intervention: Number of initial brain metastases
Number of subjects: 2092
Study: 29799968

Group type: COMPARATOR
Intervention: Daily sublingual buprenorphine with naloxone (SL-BPN/NX group)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Weekly and monthly subcutaneous buprenorphine (SC-BPN group)
Number of subjects: 428
Study: 27355499

Group type: EXPERIMENTAL
Intervention: Cash incentives ($5 plus $1 increment at each visit) conditional on attending scheduled clinic visits and accepting PMTCT services.
Number of subjects: 433

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Cash incentives (intervention group).
Number of subjects: 433
Study: 24943722

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: atovaquone-proguanil
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: artesunate-atovaquone-proguanil
Number of subjects: 338
Study: 23616548

Group type: EXPERIMENTAL
Intervention: High argument strength (AS) ads
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low argument strength (AS) ads
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: fMRI activation in the dorsomedial prefrontal cortex (dMPFC)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Immediate recall of ads
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Immediate change in intentions to quit smoking
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Urine levels of cotinine at 1 month follow-up
Number of subjects: 71
Study: 20494268

Group type: EXPERIMENTAL
Intervention: Molindone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 54
Study: 18375898

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus best supportive care (P+BSC)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 243
Study: 16337041

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (n = 24)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No statin (Control group, n = 21)
Number of subjects: 45
Study: 14602767

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10952950

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 42

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Combination of aspirin and nimesulide
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 42
Study: 8793447

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a self-management plan (SM)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Inhaled budesonide 200, 400 or 800 micrograms b.i.d. as part of a doctor-managed regimen (DM)
Number of subjects: 125
Study: 1661247

Group type: EXPERIMENTAL
Intervention: Psychologically oriented treatment for alcoholism during hospitalization (16 +/- 10 days, 1 to 4 psychotherapeutic interviews)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Psychologically oriented treatment for alcoholism
Number of subjects: 147

Group type: COMPARATOR
Intervention: Post-hospitalization psychotherapeutic program
Number of subjects: 147

Group type: COMPARATOR
Intervention: Need for medical supervision
Number of subjects: 147

Group type: COMPARATOR
Intervention: Employment status
Number of subjects: 147
Study: 571202

Group type: EXPERIMENTAL
Intervention: Whole milk with 1.75 g/kg of body weight of lactose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aqueous lactose solution
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metoclopramide with lactulose meal
Number of subjects: 14
Study: 31470168

Group type: EXPERIMENTAL
Intervention: High-implant density (HID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-implant density (LID)
Number of subjects: 0
Study: 31467510

Group type: EXPERIMENTAL
Intervention: Haemocoagulase
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adrenaline (1:1000 dilution)
Number of subjects: 100
Study: 28854574

Group type: EXPERIMENTAL
Intervention: Health Education And Relationship Training (HEART), a web-based intervention, completed in approximately 45 minutes.
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Health Education And Relationship Training (HEART)
Number of subjects: 222
Study: 25451017

Group type: EXPERIMENTAL
Intervention: Buspirone plus risperidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone plus placebo
Number of subjects: 40
Study: 23788598

Group type: EXPERIMENTAL
Intervention: Hemodialysis (ESRD patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Correlation analysis (ESRD patients)
Number of subjects: 28